Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial-Reference-Cited by-同舟云学术

Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial

Published:2023-12 Issue: Volume: Page:
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Wang Mengzhao,Fan Yun,Sun Meili,Wang Yongsheng,Zhao Yanqiu,Jin Bo,Hu Ying,Han Zhigang,Song Xia,Liu Anwen,Tang Kejing,Ding Cuimin,Liang Li,Wu Lin,Gao Junzhen,Wang Jianghong,Cheng Ying,Zhou Jianying,He Yong,Dong Xiaorong,Yao Yu,Yu Yan,Wang Huijie,Sun Si,Huang Jianan,Fang Jian,Li Wen,Wang Lin,Ren Xiubao,Zhou Chengzhi,Hu Yanping,Zhao Dahai,Yang Runxiang,Xu Fei,Huang Yijiang,Pan Yueyin,Cui Jiuwei,Xu Yan,Yang Zhenfan,Shi Yuankai

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference13 articles.

1. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics;Arcila;Mol Cancer Ther,2013

2. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: molecular heterogeneity and treatment outcome from nationwide real-world study;Yang;Lung Cancer,2020

3. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations;Bazhenova;Lung Cancer,2021

4. Real-World response and outcome in non-small cell lung cancer patients with epidermal growth factor receptor Exon 20 insertion mutations;Ou;J Clin Oncol,2021

5. Indirect comparison of Mobocertinib (TAK-788) vs real-world data outcomes in refractory NSCLC with EGFR Exon20 insertions;Horn;J Clin Oncol,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy;European Journal of Medicinal Chemistry;2024-10

2. Current clinical practice and physicians’ insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation;BMC Cancer;2024-08-23

3. Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation;Journal of Translational Medicine;2024-08-14

4. Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study;BMC Cancer;2024-08-14

5. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14